Opinion/decision on a Paediatric investigation plan (PIP): Otezla, apremilast, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0469/2020

Opinion/decision on a Paediatric investigation plan (PIP): Cerdelga, Eliglustat (tartrate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0440/2022

EMEA-002932-PIP02-21

Opinion/decision on a Paediatric investigation plan (PIP): Livmarli, Maralixibat chloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0488/2023

Opinion/decision on a Paediatric investigation plan (PIP): Veklury, remdesivir, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0439/2023

Opinion/decision on a Paediatric investigation plan (PIP): Sarclisa, Isatuximab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0144/2023

EMEA-001258-PIP01-11-M08

Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023

Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0395/2022

Antimicrobial Sales and Use (ASU) Platform: Release notes